Sign in to follow
Search Results

0 results for 'Merck'

You can use to get even better search results
December 13, 2023 | New Jersey Law Journal

Merck Hit With Antitrust Suit Over Settlement for 2 Best-Selling Cholesterol Treatments

"Merck later admitted its lawsuit had no merit because it had failed to disclose prior art to the United States Patent and Trademark Office that would have resulted in the denial of patent protection for Zetia," the complaint said. "But simply by initiating the litigation, Merck triggered a 30-month stay, which precluded the Food & Drug Administration from granting final approval of Glenmark's ANDA."
3 minute read
October 20, 2023 | Law.com

Merck, Glenmark Settle Zetia Antitrust Litigation for $70M, Including $23M in Attorney Fees

U.S. District Senior Judge Rebecca Beach Smith of the Eastern District of Virginia approved the final settlement agreement between a class of drug purchasers and pharmaceutical companies, Merck & Co., and Glenmark Pharmaceuticals, which also requires the defendants to pay one-third of the settlement fund in attorney fees, or $23 million, as well as $3.9 million in costs—as requested by plaintiffs' counsel.
4 minute read
May 19, 2023 | Corporate Counsel

Amid Troubled Merger, Albertsons Adds Experienced M&A GC

"One of the things that excites me most about this opportunity is the vital role that Albertsons Cos. plays in the communities it serves as a grocery and pharmacy retailer committed to its customers and their well-being," Moriarty said.
2 minute read
March 14, 2023 | The American Lawyer

Donald Flexner, Antitrust Titan of Boies Schiller Flexner, Dies at 81

During a legal career that spanned 55 years, Flexner helped break up AT&T while at the DOJ and went on to advise on the country's biggest mergers in private practice.
3 minute read
February 27, 2020 | Corporate Counsel

A Look Into McDonald's Fight to Protect Its In-House Counsel Privilege

"Plaintiffs' arguments boil down to nothing more than an objection to McDonald's existence as a large corporation with complex legal needs," McDonald's lawyer argues.
4 minute read
Law Journal Press | Digital Book State Antitrust Law Authors: William T. Lifland View this Book

View more book results for the query "Merck"

June 02, 2017 | The Legal Intelligencer

DOJ's Possible Antitrust Chief's Senate Confirmation Hearing

Last month, we discussed Makan Delrahim's background, including his experience litigating antitrust and intellectual property matters at the Department of Justice during the George W. Bush administration and his extensive lobbying work at Brownstein, Hyatt, Farber and Schreck. On May 10, senators from the Senate Judiciary Committee held a hearing and asked Delrahim about several matters that pose potential challenges should he be confirmed as assistant U.S. attorney of the Antitrust Division of the DOJ. For the most part, Delrahim provided candid answers, at one point even offering, "I'm an open book on this issue." Three discussions were ­particularly insightful.
17 minute read
May 01, 2017 |

Trump's Pick for Department of Justice Antitrust Division Chief

Last month we discussed Supreme Court Justice Neil Gorsuch's confirmation hearings. Specifically, we noted the Senate Judiciary Committee's failure to nail Gorsuch down on key antitrust issues, including issues he handled as an experienced antitrust lawyer and decided as a judge on the U.S. Court of Appeals for the Tenth Circuit, which we also wrote about.
18 minute read
March 28, 2017 |

What to Know About Makan Delrahim, Trump's Antitrust Division Pick

Makan Delrahim, a former top lobbyist for tech and health care companies who now serves as a deputy White House counsel, is the Trump administration's pick to lead the U.S. Justice Department's Antitrust Division, a key post that would put him, and his front-office staff, in the spotlight of in-house legal departments looking to win approval for mergers and acquisitions.
23 minute read
February 24, 2017 |

Big Suits

47 minute read
January 19, 2017 |

Price-Fixing Claims Pressed in Novo Nordisk Shareholder Suits

Danish drugmaker Novo Nordisk is facing two shareholder class actions in federal court accusing it of inflating its earning prospects and engaging in collusive pricing of its insulin drugs for diabetics.
7 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources

    • Law Firm Operational Considerations for the Corporate Transparency Act

      Brought to you by Wolters Kluwer

      Download Now

    • The Ultimate Guide to Remote Legal Work

      Brought to you by Filevine

      Download Now

    • Practical Guidance Journal: Protecting Work Product in a Generative AI World

      Brought to you by LexisNexis®

      Download Now

    • Countdown to Compliance: SEC Private Fund Reforms

      Brought to you by Ontra

      Download Now